A wave of potential Zantac lawsuits have begun, when on September 13, 2019, the US Food and Drug Administration reported that Zantac, a common heartburn medication, that is both available over the counter and by prescription, was found to have the presence of a carcinogen contaminant called N-Nitrosodimethylamine (NDMA).
Several Pharmacies have voluntarily removed Zantac from their store shelves and more are expected to follow.
As of 1/8/2020, the FDA alerted both patients and health care professionals to several voluntary recalls of Ranitidine including Zantac which are linked to NDMA a nitrosamine impurity considered a probable carcinogen that could cause cancer-based on results from laboratory studies.
The FDA advisory found the levels of contamination low, but much higher than than the FDA considers safe.
The first Zantac lawsuit was filed in California against the maker Sanofi and Boerhinger Ingelheim. Further lawsuits are expected to follow.
Appco Pharma LLC is voluntarily recalling prescription Ranitidine hydrochloride capsules. Additionally, Northwind Pharmaceuticals is voluntarily recalling prescription Ranitidine tablets manufactured by Glenmark Pharmaceutical Inc.